| Prev Close | 62.40 |
| Day Low/High | 62.13 / 63.59 |
| 52 Wk Low/High | 56.56 / 85.97 |
Gilead Sciences, Inc. (GILD)
63.33
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1253.53B |
| Market Cap | 78.22B |
| P/E Ratio | 63.67 |
| Div & Yield | N.A. (N.A) |
Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This
Some tried-and-true indicators show what's really going on with the market.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
No Bottoming Signs Yet for Gilead
Don't fight the trend of this stock.
Gilead Has 'Good News' But is it Enough?
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
Takeaways and Observations
Fear and doubt seem to have abandoned Wall Street. Dr. Hussman, while very much perma-bear, makes some good points in his weekly market commentary. See boldface. As does my pal Sir Mark Grant on CNBC's Squawk Box. I have reduced my large SPRD G...
5 Toxic Stocks to Avoid
Watch these five stocks very closely in the weeks ahead. You might be able to find a good place to jump out.
Cramer: Here's the Reason for Allergan's Remarkable Run
Static doesn't work in this industry. Pipelines work.
Tesaro, Clovis Oncology Lifting Biotechs
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
Stocks Turn Mixed as Oil Prices Rebound, Financials Lag, Disney Gains
Stocks trade mixed as energy shares rebound and financials stocks lag.
Jim Cramer Explains Why Gilead Is a Value Trap
Jim Cramer explains the problem with Gilead's stock.
Scanning the Biotech Universe
Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...
Wake Up Wall Street: European and Asian Shares Trade Higher
This is what you need to know before the opening bell.
Your Pinch Hitter Is Off and Running
I'm glad to be sitting in for Doug Kass on the Daily Diary over the next two days. There is plenty to talk about. Because we are the heart of earnings season, let's start with the quarterly results from two well-known large-cap concerns. It is going...
Gilead Sciences Expects Sales to Decline Sharply
The rest of Gilead's house is in need of serious repair.
My Takeaways and Observations
We are likely in a Trump-centric investment world in 2017. My theme that the president will make market volatility and uncertainty great again, continues. Consider the contrary, Part Deux. Mo' gold and I will accumulate under any weakness go...
The S&P 500 Chart Is Bullish
We could see a healthy pullback and still remain bullish.
My Takeaways and Observations
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
Gilead Sciences Can't Catch a Break
It is difficult to say at what level buyers may show up.
My Takeaways and Observations
The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world. I don't believe the new president will be market and economy friendly. The reflation trade is in question today. And I remain b...
Buy Stocks You Think Will Survive 'Nuclear Winter'
If you buy right, time and value should do most of the heavy lifting for you.
Biotech Sector to See M&A, Earnings Action
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
Allergan Is a Blueprint for Gilead
At least, that's the case when it comes to a technical trade.
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
5 Toxic Stocks to Watch
Watch out for these stocks as we start 2017.
3 Takeover Candidates in the Drug Space
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Beaten-Down Gilead Is My Top 2017 Pick
Shares are dirt cheap as revenues and profits have grown.
Here's What to Look for at the J.P. Morgan Healthcare Conference
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
My Takeaways and Observations
I love gold. Trade of the Week -- short Apple at $116.15. (The SoftBank investment is a non-event). Dwyerama is chillin' and I am re-establishing my ProShares UltraShort S&P500 ETF long -- back in a revolutionary mindset. As January goes......
